Switch to
More onapp

Divi's Laboratories Ltd

DIVISLAB
Health CareLabs & Life Sciences Services
LargecapWith a market cap of ₹89,088 cr, stock is ranked 63
Low RiskStock is 1.71x as volatile as Nifty
3,355.900.00 (+0.00%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CareLabs & Life Sciences Services
LargecapWith a market cap of ₹89,088 cr, stock is ranked 63
Low RiskStock is 1.71x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
30.09
PB RatioPB Ratio
7.60
Dividend YieldDiv. Yield
0.89%
Sector PESector PE
35.85
Sector PBSector PB
4.38
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

27%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Divi's Laboratories Limited is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and Intermediates. Its products include Generic APIs, Intermediates, Peptide Building Blocks and Carotenoids.

Brands

Divi's

Pharmaceutical company

Brands

Divi's

Pharmaceutical company

Financial TrendFinancial statements 

20192020202120225.105.587.039.071.351.381.982.96
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Transcript of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 14, 2022

Divi's Laboratories Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call | Download

Divi's Laboratories Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call | Download

Related Party Transaction 
Announced OnNov 14, 2022

Divi's Laboratories Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Divi's Laboratories Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Cash Dividend 
Ex. DateAug 11, 2022

Final • Div/Share: ₹ 30

See all events